| domain | evidence-based findings | ontology suggestions | evidence limitations |
|---|---|---|---|
| 1. Disease information | Denys-Drash syndrome (DDS) is a rare Mendelian WT1-associated syndrome defined by the classic triad of early-onset nephropathy, Wilms tumor predisposition, and 46,XY disorder/difference of sex development (DSD); Open Targets lists disease identifier MONDO:0008682 and strongest target association with WT1. Evidence base is aggregated disease-level plus individual case/cohort reports, not EHR-derived population surveillance (pqac-00000000, pqac-00000002) | MONDO:0008682; MeSH term suggestion: *Denys-Drash Syndrome* if used locally; NCIT disease term suggestion: *Denys-Drash Syndrome* | OMIM, Orphanet, ICD-10/11, and MeSH numeric identifiers were not verified in available tool context and should be left unfilled until source-confirmed |
| 2. Etiology | Primary cause is heterozygous germline WT1 pathogenic variation, classically in exons 8 or 9 affecting zinc-finger DNA-binding domains; inheritance is autosomal dominant, but many cases are de novo. No established environmental or infectious causes were identified in available evidence (pqac-00000002, pqac-00000003) | HGNC: WT1; SO variant classes: missense_variant, frameshift_variant, splice_donor_variant, splice_region_variant | Gene-environment interaction and protective factors are not established for DDS in available evidence |
| 3. Phenotypes | Core renal phenotype is diffuse mesangial sclerosis (DMS) causing congenital/infantile nephrotic syndrome, proteinuria, edema, and progression to kidney failure, often before age 5; extrarenal phenotypes include Wilms tumor and male pseudohermaphroditism/46,XY DSD with ambiguous or female external genitalia (pqac-00000001, pqac-00000002) | HPO: HP:0000093 Proteinuria; HP:0000100 Nephrotic syndrome; HP:0005567 Diffuse mesangial sclerosis; HP:0003774 Stage 5 chronic kidney disease; HP:0000830 Ambiguous genitalia; HP:0000119 Abnormality of the genitourinary system; HP:0002667 Nephroblastoma | Precise phenotype frequencies vary by case series; robust pooled percentages were not available in retrieved context |
| 4. Genetic/molecular information | WT1 is the main causal gene. Open Targets also shows weaker disease associations for GPC3 and WTIP, but these are not established primary causes of classic DDS. Functional consequence is loss of normal WT1 transcriptional regulation, with evidence supporting dominant-negative or threshold-reduction effects in some models (pqac-00000000, pqac-00000001) | HGNC:12796 WT1; GO:0003700 DNA-binding transcription factor activity; GO:0006355 regulation of DNA-templated transcription | Population allele frequencies, ClinVar classifications, and full variant catalog were not available from current tool context |
| 5. Environmental information | No specific environmental, lifestyle, toxin, or infectious trigger is established as causal for DDS; disease is chiefly genetic (pqac-00000002, pqac-00000003) | ExO/CHEBI not clearly applicable | Absence of evidence should not be interpreted as proof of no modifiers; targeted environmental studies are lacking |
| 6. Mechanism / pathophysiology | Causal chain: WT1 pathogenic variant leads to abnormal WT1 transcription factor function, which leads to impaired metanephric/podocyte developmental programs and altered podocyte identity, which leads to slit diaphragm/cytoskeletal and growth-factor dysregulation, which leads to DMS/proteinuria and progressive kidney failure; in parallel, abnormal genitourinary development leads to 46,XY DSD, and tumor-predisposition pathways increase Wilms tumor risk. Mouse and review evidence implicate WT1 control of FGF, BMP-pSMAD, FGF8/WNT4, and podocyte transcription factors MAFB, LMX1B, FOXC2, TCF21 (pqac-00000001) | GO:0032835 glomerulus development; GO:0072006 nephron development; GO:1903671 regulation of sprouting angiogenesis; GO:0045666 positive regulation of neuron differentiation not primary; CL:0000653 podocyte; CL:0000099 mesangial cell; UBERON:0001285 glomerulus | Much detailed mechanism is inferred from mouse/review data rather than directly demonstrated in large human mechanistic cohorts |
| 7. Anatomical structures affected | Primary organs: kidney and gonads/genitourinary tract; secondary oncologic involvement: kidney Wilms tumor. At tissue/cell level, glomerulus—especially podocytes and mesangium—is central. Subcellularly, WT1 is a nuclear transcription factor (pqac-00000001, pqac-00000002) | UBERON:0002113 kidney; UBERON:0001285 glomerulus; UBERON:0000473 gonad; CL:0000653 podocyte; CL:0000099 mesangial cell; GO:0005634 nucleus | Broader systemic involvement is limited in available evidence; lateralization is mainly relevant for unilateral/bilateral Wilms tumor but DDS-specific rates were not retrieved |
| 8. Temporal development | Onset is typically congenital to early childhood for nephropathy; progression is rapid, with end-stage kidney disease (ESKD) often in early childhood. The transplant-focused study notes median transplant age 3.6 years in one French cohort description; registry/cohort evidence also supports early pediatric progression (pqac-00000001, pqac-00000003) | HPO onset modifiers: congenital onset, infantile onset, childhood onset | Natural-history staging data are sparse; remission is generally not expected without renal replacement/transplant strategies |
| 9. Inheritance and population | DDS is rare, classically autosomal dominant, frequently sporadic/de novo. Sex-development manifestations are especially relevant in 46,XY individuals. No reliable prevalence/incidence estimate was available in current evidence. Registry evidence indicates need for multicenter collection due to rarity (pqac-00000002, pqac-00000003) | GENO:0000135 autosomal dominant inheritance; HPO: HP:0001417 X-linked not applicable | Penetrance, founder effects, carrier frequency, and population-specific prevalence could not be quantified from available context |
| 10. Diagnostics | Diagnostic workup combines clinical suspicion (early nephrotic syndrome/DMS, Wilms tumor, ambiguous genitalia/46,XY DSD), kidney pathology, imaging for renal masses, karyotype/DSD assessment, and confirmatory WT1 molecular testing. Differential includes broader WT1-related disorders such as Frasier syndrome and isolated WT1 nephropathy (pqac-00000002, pqac-00000003) | HPO/NCIT suggestions: kidney biopsy, renal ultrasound, karyotyping, sequence analysis of WT1 | No DDS-specific formal diagnostic criteria document was retrieved; recommendations are based on expert practice and WT1-related disorder literature |
| 11. Outcome / prognosis | Morbidity is driven by steroid-resistant nephrotic syndrome, ESKD, tumor risk, DSD-related surgical/endocrine issues, and transplant complications. Recent registry/trial context highlights post-transplant lymphoproliferative disorder (PTLD) concern, with French data cited in protocol suggesting 20% PTLD risk versus ~4% in general transplant populations (pqac-00000003) | HPO: HP:0003774 Stage 5 CKD; NCIT: renal replacement therapy; PTLD term suggestion | Survival and long-term life expectancy estimates were not available in current verified context |
| 12. Treatment | No disease-modifying WT1-targeted therapy is established. Management is supportive and complication-directed: nephrotic syndrome care, nephrectomy in selected cases, dialysis, kidney transplantation, Wilms tumor treatment per pediatric oncology protocols, and multidisciplinary DSD care. Recent single-center WT1-associated transplant cohort reported no disease recurrence and preserved graft function after median 32 months, though not DDS-only (summarized in retrieved literature) (pqac-00000003) | NCIT: Nephrectomy; Dialysis; Kidney Transplantation; Chemotherapy Regimen; Gonadectomy when indicated in DSD/WT1 care | Evidence is largely observational, retrospective, or extrapolated from WT1-associated disease and Wilms tumor management rather than DDS-specific trials |
| 13. Prevention | Primary prevention of genetic occurrence is not available. Secondary prevention centers on early genetic diagnosis and tumor/renal surveillance in at-risk children; tertiary prevention involves CKD management, transplant planning, and long-term DSD/oncology follow-up. Genetic counseling is central for family planning (pqac-00000002, pqac-00000003) | NCIT: Genetic Counseling; Surveillance; Ultrasonography | Exact surveillance intervals were not source-verified in current context and should not be over-specified here |
| 14. Other species / natural disease | No naturally occurring veterinary analogue was established in available context. Comparative relevance comes mainly from engineered mouse models rather than spontaneous disease in other species (pqac-00000001) | NCBI Taxon suggestion if needed for negative annotation: *Mus musculus* 10090 for model, not natural disease | OMIA-style natural disease evidence was not retrieved |
| 15. Model organisms and current research | Mouse DDS models carrying WT1 missense alleles (for example p.Arg394Trp) recapitulate glomerulosclerosis/DMS-like renal disease and identified altered podocyte transcriptional targets including *Scel*, *Sulf1*, and *Cyp26a1*; in vitro podocyte proteomic work supports dedifferentiation-associated changes. Current research is largely observational/registry-based, including WT1 mutation registry NCT01252901, UK rare kidney disease registry NCT06065852, rare disease natural history registry NCT01793168, and PTLD risk study NCT07605884 (pqac-00000001, pqac-00000003) | NCBI Taxon:10090; CL:0000653 podocyte; GO:0006351 transcription, DNA-templated; NCIT: Disease Registry | 2023-2024 DDS-specific interventional trials, spatial transcriptomics, or multi-omics integration studies were not identified in available tool context |


*Table: This table summarizes evidence-based, knowledge-base-ready findings for Denys-Drash syndrome across all 15 requested domains. It highlights what is supported by available human, mouse, in vitro, and registry evidence while explicitly marking unverified identifiers and data gaps.*